Pretty much ANY antidepressant, including chocolate.

This is probably far too much information, but I'll paste the
information from Medscape's database. This class of drug, which still
has applications although never the first choice, has one of the widest
range of bad interactions of ANY class of medication.  You need to have
about a two-week period between the last dose of any other
antidepressant I can think of, and the first dose of MAOI:

Concomitant use of MAO inhibitors and certain food or prescription or
nonprescription (over-the-counter, OTC) drugs can result in interactions
that have the potential to cause hypertensive crisis due to the release
and potentiation of catecholamines similar to that experienced in
pheochromocytoma. The severity and consequences of such interactions
vary among individuals. If only minor increases in blood pressure occur,
patients may be unaware of the interactions. However, if substantial and
rapid increases in blood pressure (an increase of 30 mm Hg or more in
systolic blood pressure within 20 minutes) occur, patients may
experience symptoms associated with subarachnoid hemorrhage or cardiac
failure (sudden severe occipital headache, palpitations) if the cerebral
vasculature or cardiac musculature are already weakened. (See
Hypertensive Crisis under Cautions: Cardiovascular Effects.)

Food

Hypertensive crises have occurred following ingestion of foods
containing large amounts of tyramine or tryptophan in some patients
receiving MAO inhibitors. In general, patients should avoid protein
foods that have undergone protein breakdown by aging, fermentation,
pickling, smoking, or bacterial contamination; protein extracts and
liquid or powdered dietary supplements also should be avoided. Patients
should be specifically instructed not to eat foods such as cheese,
particularly strong or aged varieties (e.g., cheddar, Camembert,
Stilton) and processed cheese; sour cream; wine, especially chianti,
champagne, and alcohol-free or reduced-alcohol wine products; beer,
including alcohol-free and reduced-alcohol beers; pickled herring;
anchovies; caviar; shrimp paste; liver, especially chicken liver; dry
sausage (e.g., Genoa salami, hard salami, pepperoni, Lebanon bologna);
figs, particularly if overripe, or canned figs; raisins; bananas or
avocados, particularly if overripe; chocolate; soy sauce; bean curd;
yeast extracts (including brewer?s yeast in large quantities); yogurt;
papaya products, including certain meat tenderizers; and pods of broad
beans (e.g., fava beans). Excessive amounts of caffeine may also
reportedly precipitate hypertensive crisis. Specialized references on
food constituents or a dietician should be consulted for more specific
information on the tyramine content of foods and beverages.

Sympathomimetic Agents and Catecholamine-releasing Agents

Because some patients appear to be particularly sensitive to the
hypertensive effects of sympathomimetic agents during MAO inhibitor
therapy, centrally acting sympathomimetic agents (e.g., amphetamines) or
peripherally acting sympathomimetic agents, including prescription or
nonprescription cold, hay fever, or weight-reducing preparations that
contain pressor agents (e.g., ephedrine, phenylpropanolamine), should
not be administered concomitantly with an MAO inhibitor.

Parenteral or oral administration of reserpine or guanethidine in
patients receiving MAO inhibitors may cause a severe pressor response as
a result of a sudden release of accumulated catecholamines. Therefore,
the manufacturers of MAO inhibitors do not recommend concomitant use of
guanethidine in patients receiving an MAO inhibitor and also recommend
that reserpine be administered cautiously in patients receiving MAO
inhibitors.

Levodopa and other Catecholamines

Hypertension, headache, hyperexcitability, and related symptoms
reportedly have occurred in patients receiving MAO inhibitors
concurrently with methyldopa, dopamine, or levodopa. It has been
suggested that use of a decarboxylase inhibitor (e.g., carbidopa) with
levodopa may prevent hypertensive reactions during concomitant therapy
with an MAO inhibitor.

?Drugs Associated with Serotonin Syndrome

Serotonin syndrome may occur in patients receiving MAO inhibitors in
combination with other serotonergic drugs. Although the syndrome appears
to be relatively uncommon and usually mild in severity, serious
complications, including seizures, disseminated intravascular
coagulation, respiratory failure, severe hyperthermia, and death
occasionally have been reported. The precise mechanism of the syndrome
is not fully understood; however, it appears to result from excessive
serotonergic activity in the CNS, probably mediated by activation of
serotonin 5-HT1A receptors. The possible involvement of dopamine and
5-HT2-receptors also has been suggested, although their roles remain
unclear.

The syndrome most commonly occurs when 2 or more serotonergic agents
with different mechanisms of action are administered either concurrently
or in close succession. Serotonergic agents include those that increase
serotonin synthesis (e.g., the serotonin precursor tryptophan),
stimulate synaptic serotonin release (e.g., some amphetamines,
dexfenfluramine [no longer commercially available in the US],
fenfluramine [no longer commercially available in the US]), inhibit the
reuptake of serotonin after release (e.g., selective serotonin-reuptake
inhibitors [SSRIs], tricyclic antidepressants, trazodone,
dextromethorphan, meperidine, tramadol), decrease the metabolism of
serotonin (e.g., MAO inhibitors), have direct serotonin postsynaptic
receptor activity (e.g., buspirone), or nonspecifically induce increases
in serotonergic neuronal activity (e.g., lithium salts).

The combination of MAO inhibitors and SSRI antidepressants (e.g.,
fluoxetine) appears to be responsible for most of the recent case
reports of serotonin syndrome. The syndrome also has been reported when
MAO inhibitors have been combined with tricyclic antidepressants,
tryptophan, meperidine, or dextromethorphan. In rare cases, serotonin
syndrome reportedly has occurred with the recommended dosage of a single
serotonergic agent (e.g., clomipramine) or during accidental overdosage
(e.g., sertraline intoxication in a child). Some other drugs that have
been implicated in certain circumstances include buspirone,
bromocriptine, dextropropoxyphene, methylenedioxymethamphetamine (MDMA;
??ecstasy??), and selegiline (a selective MAO-B inhibitor). Other drugs
that have been associated with the syndrome but for which less
convincing data are available include carbamazepine, fentanyl, and
pentazocine.

Clinicians should be aware of the potential for serious, possibly fatal
reactions associated with serotonin syndrome in patients receiving 2 or
more drugs that increase the availability of serotonin in the CNS, even
if no such interactions with the specific drugs have been reported to
date in the medical literature. Pending further data, all drugs with
serotonergic activity should be used cautiously in combination and such
combinations avoided whenever clinically possible. Some clinicians state
that patients who have experienced serotonin syndrome may be at higher
risk for recurrence of the syndrome upon reinitiation of serotonergic
drugs. Pending further experience in such cases, some clinicians
recommend that therapy with serotonergic agents be limited following
recovery. In cases in which the potential benefit of the drug is thought
to outweigh the risk of serotonin syndrome, lower potency agents and
reduced dosages should be used, combination serotonergic therapy should
be avoided, and patients should be monitored carefully for symptoms of
serotonin syndrome. For further information on serotonin syndrome,
including manifestations and treatment, see Serotonin Syndrome under
Drug Interactions: Drugs Associated with Serotonin Syndrome, in
Fluoxetine Hydrochloride 28:16.04.20.

Selective Serotonin-reuptake Inhibitors

Concurrent use of selective serotonin-reuptake inhibitors (SSRIs) and
MAO inhibitors potentially is hazardous and may result in serotonin
syndrome. Probably because of its extensive clinical use and the
prolonged elimination half-life of both fluoxetine and norfluoxetine,
fluoxetine has been the SSRI most commonly implicated in serotonin
syndrome when combined with MAO inhibitor therapy. In at least 2 cases,
serotonin syndrome has developed when MAO inhibitor therapy has been
initiated after the discontinuance of fluoxetine therapy. Shivering,
diplopia, nausea, confusion, and anxiety reportedly occurred in one
patient 6 days after discontinuance of fluoxetine therapy and 4 days
after initiation of tranylcypromine therapy; signs and symptoms resolved
without apparent sequelae within 24 hours following discontinuance of
the MAO inhibitor in this patient. In another case, the initiation of
tranylcypromine therapy more than 5 weeks after discontinuance of
fluoxetine reportedly resulted in serotonin syndrome. The manufacturer
of fluoxetine, the manufacturers of MAO inhibitors, and some clinicians
state that concurrent administration of fluoxetine and MAO inhibitors is
contraindicated. Because both fluoxetine and its principal metabolite
have relatively long half-lives, the manufacturer of fluoxetine, the
manufacturers of MAO inhibitors, and some clinicians recommend that at
least 5 weeks elapse between discontinuance of fluoxetine therapy and
initiation of MAO inhibitor therapy, since administration of an MAO
inhibitor prior to elapse of this time may increase the risk of serious
adverse effects. Although the manufacturers of some MAO inhibitors
(i.e., phenelzine) recommend that at least 10 days elapse following
discontinuance of MAO inhibitor therapy prior to initiation of
fluoxetine therapy, based on clinical experience with concurrent
administration of tricyclic antidepressants and MAO inhibitors, the
manufacturers of fluoxetine and the manufacturers of some MAO inhibitors
(e.g., selegiline, tranylcypromine) recommend that at least 2 weeks
elapse following discontinuance of an MAO inhibitor prior to initiation
of fluoxetine therapy.

Other SSRI antidepressants, including sertraline and citalopram, also
have been associated with serotonin syndrome when given in combination
with MAO inhibitors. Because of the potential risk of serotonin syndrome
when SSRIs are combined with MAO inhibitor therapy, the manufacturers of
fluvoxamine, paroxetine, and sertraline currently recommend that a
drug-free interval of at least 2 weeks elapse when switching from an MAO
inhibitor to these agents or when switching from these agents to an MAO
inhibitor.

Moclobemide, a selective and reversible MAO-A inhibitor (not
commercially available in the US), also has been associated with
serotonin syndrome and such reactions have been fatal in several cases
in which the drug was given in combination with citalopram or with
clomipramine. Pending further experience with such combinations, some
clinicians recommend that concurrent therapy with moclobemide and SSRIs
be used only with extreme caution and that the SSRI should have been
discontinued for some time (depending on the elimination half-lives of
the drug and its active metabolites) before initiating moclobemide
therapy.

Tryptophan

Although tryptophan sometimes has been used to enhance the
antidepressant activity of MAO inhibitors, serotonin syndrome, which was
fatal in at least one case, has been reported in a limited number of
patients receiving these drugs in combination either with or without
concurrent lithium therapy. While the mechanism for this interaction has
not been fully elucidated, it has been suggested that these adverse
effects resemble serotonin syndrome and therefore may result from a
marked increase in serotonin availability in the CNS when these agents
are administered concurrently. Behavioral and neurologic syndromes,
including disorientation, confusion, amnesia, delirium, agitation,
hypomanic signs, ataxia, myoclonus, hyperreflexia, shivering, ocular
oscillations, and Babinski signs, also have been reported in patients
receiving MAO inhibitors and tryptophan concomitantly. Pending further
evaluation of this potential interaction, clinicians should be aware
that toxic reactions may occur when MAO inhibitors and tryptophan are
administered concomitantly.

Buspirone

Elevations in blood pressure have been observed in several patients
receiving an MAO inhibitor and buspirone concomitantly; no adverse
sequelae were associated with these elevations. Buspirone may have been
partially responsible for a case of serotonin syndrome that resulted in
the death of a patient receiving buspirone, an MAO inhibitor
(tranylcypromine), and fluoxetine concomitantly. Pending accumulation of
additional data, it is recommended that MAO inhibitors not be used
concomitantly with buspirone. Some manufacturers recommend that at least
10 days elapse between discontinuance of MAO inhibitor therapy and
administration of buspirone.

?Tricyclic Antidepressants

Concomitant administration of MAO inhibitors and tricyclic
antidepressants is contraindicated, and it generally is recommended that
at least 2 weeks should elapse between discontinuance of tricyclic
antidepressant therapy or MAO inhibitor therapy and initiation of
therapy with the other class of drugs. Serious, sometimes fatal,
reactions including hyperpyrexia, confusion, diaphoresis, myoclonus,
rigidity, seizures, cardiovascular disturbances, and coma have occurred
in patients who received an MAO inhibitor and a tricyclic antidepressant
concomitantly. Patients receiving therapeutic dosages of an oral MAO
inhibitor and an oral tricyclic antidepressant concomitantly generally
have experienced nonfatal hyperpyrexia, hypertension, tachycardia,
confusion, and seizures; most reported cases of hyperpyretic crises,
severe seizures, or death occurred following overdosage or parenteral
administration of one or both drugs. Although the mechanism has not been
clearly established, these reactions resemble serotonin syndrome and may
be caused by excessive serotonergic activity in CNS. (See Drug
Interactions: Drugs Associated with Serotonin Syndrome.)

?CNS Depressants

Several manufacturers caution that MAO inhibitors may be additive with,
or may potentiate the action of, CNS depressants such as opiates or
other analgesics, barbiturates or other sedatives, anesthetics, or
alcohol. CNS depressants should be administered cautiously to patients
receiving MAO inhibitors in order to avoid excessive sedation and acute
hypotension; a reduction in dosage of the CNS depressant agent(s) may be
necessary. One manufacturer recommends that, if emergency surgery is
necessary in a patient receiving an MAO inhibitor, the dose of opiate,
sedative, analgesic, and other premedication be reduced to one-fourth to
one-fifth the usual dose.

Meperidine

Meperidine should not be used in patients receiving MAO inhibitors since
severe, generally immediate reactions, including excitation, sweating,
rigidity, and hypertension, suggestive of serotonin syndrome, have
occurred. Circulatory collapse and death have also occurred following
administration of a single dose of meperidine in some patients receiving
an MAO inhibitor.

Dextromethorphan

Concomitant use of MAO inhibitors and dextromethorphan (ingested as a
lozenge) has been reported to cause brief episodes of psychosis or
bizarre behavior. Cases of apparent serotonin syndrome, including at
least 2 fatalities, have been reported in patients receiving concurrent
MAO inhibitor and dextromethorphan therapy. Dextromethorphan
preparations should not be used in patients receiving an MAO inhibitor.

?Bupropion

Studies in animals using phenelzine have shown that the acute toxicity
of bupropion is enhanced by the MAO inhibitor. Concomitant use of an MAO
inhibitor and bupropion is contraindicated, and it is suggested that at
least 14 days elapse between discontinuance of MAO inhibitor therapy and
initiation of bupropion therapy.

?Anesthetics

The hypotensive and CNS depressant effects of general anesthetics may be
exaggerated in patients receiving MAO inhibitors. Since inhibition of
monoamine oxidase may persist for several days following discontinuance
of therapy, some manufacturers suggest that MAO inhibitors be
discontinued for at least 7?14 days prior to elective surgery to allow
time for recovery of enzymatic activity before general anesthetics are
used. If emergency surgery is necessary in a patient receiving an MAO
inhibitor, the dose of the general anesthetic should be carefully
adjusted.

Patients receiving MAO inhibitors should not be given cocaine or local
anesthetics that contain sympathomimetic vasoconstrictors, since
hypertension may result.

Because MAO inhibitors may potentiate the hypotensive effect of local
anesthetics used in spinal anesthesia, these agents should be used with
caution in patients receiving MAO inhibitors.

?Disulfiram

MAO inhibitors should probably be used with caution in patients
receiving disulfiram. In one study in animals receiving large
intraperitoneal doses of disulfiram and the d- or l-isomer of
tranylcypromine, severe toxicity, including seizures and death,
occurred. However, in other studies in animals receiving large oral
doses of disulfiram and racemic tranylcypromine, no adverse interaction
was reported.

?Metrizamide

Animal studies suggest an increased risk of seizures when metrizamide
(no longer commercially available in the US) is administered
concurrently with drugs that lower the seizure threshold; however, the
clinical importance of such an interaction has not been clearly
established. The manufacturer of metrizamide has stated that MAO
inhibitors should not be used concomitantly in patients receiving the
contrast medium. The manufacturer of metrizamide also stated that MAO
inhibitors should be discontinued, if possible, at least 48 hours before
and for at least 24?48 hours after administration of metrizamide.

?Diuretics and Hypotensive Agents

In general, MAO inhibitor antidepressants should not be administered
concomitantly with diuretics or hypotensive agents since a marked
hypotensive effect may occur.

?Drugs with Anticholinergic Activity

Some manufacturers state that anticholinergic antiparkinsonian drugs
should be used with caution in patients receiving MAO inhibitors, since
severe reactions have reportedly occurred when these drugs were used
concurrently; however, additional information is needed to determine the
clinical importance of this potential interaction. It also should be
considered that MAO inhibitors may prolong and intensify some
anticholinergic effects (e.g., dryness) of antihistamines.